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One of the principal goals in tumor immune prophylaxis and tumor therapy is the induction of antitumor
responses by generating sufficient numbers of tumor antigen-specific helper T (Th)1 cells and cytotoxic T
lymphocytes (CTLs). We have demonstrated that the administration of cytosine-phosphate-guanosine-
oligodeoxynucleotide (CpG-ODN) through tape-stripped skin induced a Th1-type immune response and
suggested that the skin is a potential site for vaccination. CpG-ODN induces the expression of cyclooxygenase
(COX)-2, and its product prostaglandin (PG) E2 underlies an immunosuppressive network, therefore it is a
simple strategy to use a COX-2 inhibitor for tumor vaccination with CpG-ODN. In this study, we examined
whether a COX-2 inhibitor enhances the antitumor immune response induced by CpG-ODN with model tumor
antigen, ovalbumin (OVA), applied to tape-stripped skin in mice. The COX-2 inhibitor remarkably enhanced
antigen-specific Th1-type immune responses and generation of CTLs induced by transcutaneous vaccination
with CpG-ODN and OVA. PGE2 and IL-10 levels in the skin were significantly decreased and production of IL-12
was enhanced. This vaccination also induces an effective antitumor immunity in tumor-challenged mice. These
results suggested that transcutaneous vaccination with a COX-2 inhibitor, CpG-ODN, and tumor antigen is a
very simple and cost-effective strategy for tumor vaccine and may be readily achievable.
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INTRODUCTION
CD4þ helper T (Th) cells are subdivided into at least two
subsets, Th1 and Th2, on the basis of the cytokines they
secrete (Fiorentino et al., 1989; Mosmann and Coffman,
1989). Th1-like immune responses enhance cellular immu-
nity in association with increased levels of Th1-like cytokines
such as IL-2 and IFN-g and upregulated activity of CTLs,
indicating that the suppression of Th1 cells and CTLs can
result in an acceleration of tumor growth (Tuttle et al., 1993).
One of the principal goals in tumor immune prophylaxis and
tumor therapy is the induction of antitumor responses by
generating sufficient numbers of tumor antigen-specific Th1
cells and cytotoxic T lymphocytes (CTLs). Therefore, it is very
important for tumor immune therapy to establish efficient Th1
and CTL priming strategies.
Unmethylated CpG dinucleotides flanked by certain bases
(CpG-motif), which are present in bacterial DNA, have been
shown to be immunostimulatory (Krieg, 2002). Previous
studies have found that both the bacterial CpG-motif and
synthetic oligodeoxynucleotides containing a CpG-motif
(CpG-ODN) activate cells such as B cells, macrophages,
and dendritic cells (DC), through toll-like receptor-9 (Krieg,
2002; Agrawal and Kandimalla, 2003). Signaling through
toll-like receptor-9 leads to the secretion of large amounts of
proinflammatory cytokines such as type-I IFN, IL-1b, IL-6,
tumor necrosis factor-a, and IL-12 (Hemmi et al., 2003; Spies
et al., 2003). IL-12 acts on T and natural killer (NK) cells
inducing the production of cytokines, primarily IFN-g,
enhancing NK cell cytotoxic activity. CpG-ODN also induces
the production of great numbers of CTLs which have
antitumor effects (Davis et al., 1998; Miconnet et al.,
2002). Consequently, CpG-ODN could be effective as an
adjuvant for cellular and humoral immunities (Klinman et al.,
2004).
Cyclooxygenase (COX)-2 and its product prostaglandin
(PG) E2 underlie an immunosuppressive network that is
important in tumor therapy and vaccination (Howe et al.,
2005; Sharma et al., 2005). CpG-ODN induces COX-2
expression and PGE2 production in DCs and macrophages
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(Chen et al., 2001; Ghosh et al., 2001). PGE2 is a potent
inhibitor of Th1-type immune responses (Katamura et al.,
1995), inhibiting IFN-g production as well as IL-12 and
IL-12R expression (Abe et al., 1997; Wu et al., 1998), and is
also a potent inducer of production of the immunosuppres-
sive cytokine IL-10 (Harizi et al., 2002). Furthermore, IL-10
suppresses the production IL-12 by antigen-presenting cells
(APCs), therefore APCs from IL-10 knockout mice are
induced to produce a large quantity of IL-12 by CpG-ODN
(Yi et al., 2002). Thus it is very simple strategy to use a COX-2
inhibitor for tumor vaccination with CpG-ODN.
The skin has recently become a target site in the
development of non-invasive vaccine technologies (Beignon
et al., 2002; Klimuk et al., 2004). We have reported that the
administration of CpG-ODN through tape-stripped skin in-
duced a Th1-type immune response and suggested that the skin
is a potential site for vaccination (Inoue et al., 2005a, b). It is
also favorable that APCs, especially langerhans cells (LCs) and
dermal DCs, are common in the skin and easy to target.
In this study, we examined whether a COX-2 inhibitor
enhances antitumor immune responses induced by CpG-
ODN with model tumor antigen ovalbumin (OVA), applied
to tape-stripped skin in mice. The COX-2 inhibitor remark-
ably enhanced the Th1-type immune response and genera-
tion of CTLs, and a transcutaneous vaccination with the
inhibitor, CpG-ODN and OVA was effective in inducing
antigen-specific antitumor immunity in vivo. These results
suggested that transcutaneous vaccination with a COX-2
inhibitor, CpG-ODN, and tumor antigen is an effective
approach.
RESULTS
COX-2 inhibitor enhances CpG-ODN-induced Th1-dominant
immune responses on transcutaneous vaccination
CpG-ODN induces COX-2 expression and its product PGE2
underlies an immunosuppressive network (Howe et al., 2005;
Sharma et al., 2005). Therefore it is a very simple strategy to
use a COX-2 inhibitor to enhance the effect of CpG-ODN.
First we examined whether the COX-2 inhibitor NS3-398,
enhances the antigen-specific Th1-dominant immune re-
sponse induced by CpG-ODN, applied to tape-stripped skin
in mice. Spleen cells were prepared on day 7 from the last
vaccination, and were incubated in the presence of 2 mg/ml
of OVA for 24 hours. Supernatants were collected and
concentrations of IFN-g were evaluated by ELISA. As shown
in Figure 1a, the production of IFN-g increased on the co-
application of OVA and CpG-ODN, and upregulation of IFN-
g production was observed in mice, which were treated with
the COX-2 inhibitor (NS-398). The co-application of OVA
and NS-398 did not upregulate the IFN-g production.
Furthermore, the vaccination with control antigen (BSA) did
not induce the IFN-g production (Figure 1b). These results
suggested that antigen-specific immune responses are in-
duced and antigen-nonspecific immune responses, such as
NK and NK T cell-mediated IFN-g production, are not shown
in this experiment. Next we examined the production of
OVA-specific IgG2a antibody, which is considered to be a
Th1-like Ig isotype. OVA-specific IgG2a production in-
creased drastically when NS-398 was applied with CpG-
ODN from the skin (Figure 1c). These findings suggested that
co-application of CpG-ODN with a COX-2 inhibitor to tape-
stripped skin leads to enhanced Th1-dominant immune
responses.
Effect of vaccination route on IFN-c production
Vaccines consisting of CpG-ODN and OVA, with or without
NS-398, were administered by different routes, intravenously
(i.v.), intraperitoneally (i.p.), or transcutaneously, and the
level of production of IFN-g was determined. Seven days after
the last vaccination, the spleen cells were prepared, and
IFN-g concentrations in the culture supernatant were
evaluated by ELISA. In each case, levels of IFN-g were
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Figure 1. A COX-2 inhibitor enhances CpG-ODN-induced Th1-dominant immune responses following a transcutaneous vaccination. (a, b) NS-398 (25 mg),
CpG-ODN (50 mg), and OVA or BSA (50 mg) were applied to shaved abdominal skin after barrier disruption by tape stripping (six times). BSA was used for control
antigen. Spleen cells (5 105 per well) were prepared 7 days after the last vaccination, and incubated in the presence of OVA (2 mg/ml) for 24 hours. The
concentration of IFN-g in the culture supernatant was evaluated by ELISA. OVA (50 mg) (m), NS-398 (25mg) plus OVA (50 mg) plus CpG-ODN (50mg) (J), buffer
plus OVA (50 mg) plus CpG-ODN (50 mg) (K), and OVA (50 mg) plus CpG-ODN (50 mg) (’) were applied to the tape-stripped skin. Sera were collected 2 weeks
after the last vaccination and the OVA-specific IgG2a titer was evaluated by ELISA (c). Each value represents the mean7SD for five mice. *Po0.05 compared
with OVA plus CpG-ODN. #Po0.05 compared with OVA.
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increased in CpG-ODN plus OVA-treated mice, and en-
ormous amount of IFN-g were detected following an i.v.
vaccination (Figure 2). On the other hand, in the case of
vaccination with NS-398, upregulation of IFN-g production
was observed when the vaccine was administered from the
skin but not i.p. and i.v., and the level of IFN-gwas the same as
on the i.v. administration of CpG-ODN and OVA (Figure 2).
No enhancement of IFN-g production was observed when NS-
398 was administered i.p. or i.v. These results suggest that skin
is the potentially the best site for the induction of a Th1-
dominant immune response by a COX-2 inhibitor.
Effect of COX-2 inhibitor on cytokine production in the skin
Next we examined the mechanisms of the enhancement of
Th1-type immune responses induced by the transcutaneous
vaccination with the COX-2 inhibitor. It is reported that CpG-
ODN promotes Th1-like immune responses with the produc-
tion of PGE2 and IL-10, which are considered to be suppressive
mediators in vivo (Chen et al., 2001). Thus, we first examined
the changes in cytokine levels in the skin 12 hours after the
transcutaneous vaccination. IL-12, IL-10, and PGE2 levels
increased significantly when OVA was co-applied with CpG-
ODN (Figure 3). On the other hand, the application of NS-398
drastically increased IL-12 production and decreased signifi-
cantly IL-10 and PGE2 production in the skin (Figure 3). These
findings suggest that NS-398 suppresses the production of
PGE2 and IL-10 in the skin and this suppression induces the
production of a large quantity of IL-12.
Effect of COX-2 inhibitor on migration of APC and mRNA
expression in draining lymph nodes
It is reported that the number of allergen-bearing LCs in the
LN was significantly greater in IL-10 knockout mice than in
wild-type mice, and these mice demonstrated a greater
increase in production of tumor necrosis factor-a and IL-1b
which induce the migration of LCs to the LN in the allergen-
exposed epidermis (Wang et al., 1999). So we next examined
the effect of a COX-2 inhibitor on the migration of APCs to
draining LNs. NS-398, CpG-ODN, and Alexa-488-conju-
gated OVA were applied to tape-stripped skin, and the
draining LNs were removed 24 hours later. LN single cells
were treated with anti-major histocompatibility complex
(MHC) class II mAb or anti-CD11c mAb and then double-
positive cells were analyzed on FACScan. As shown in Figure
4a, application of CpG-ODN to the tape-stripped skin
significantly enhanced the migration of Alexa-488 and
MHC class II double-positive cells, but any significant
differences between CpG-ODN and CpG-ODN plus NS-
398 was not observed. In case of CD11c analysis, the
migration of Alexa-488 and CD11c double-positive cells to
draining LNs were significantly enhanced when NS-398 was
co-applied (Figure 4a). These results suggest that the co-
application with NS-398 especially enhances the migration
of antigen-bearing-CD11c-positive cells to the draining LNs.
Next we examined the effect of these APCs on T-cell
differentiation in the draining LN. NS-398, CpG-ODN and
OVA were applied to the tape-stripped skin, then draining
LNs were removed, and the cytokine mRNA expression in the
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Figure 2. The COX-2 inhibitor enhances the effect of the transcutaneous
vaccination but not the i.p. or i.v. vaccination. NS-398 (25 mg), OVA (50 mg),
and CpG-ODN (50 mg) were applied transcutaneously, i.p. or i.v. Spleen cells
(5105 per well) were prepared 7 days after the last vaccination, and
incubated in the presence of OVA (2 mg/ml) for 24 hours. The concentration
of IFN-g in the culture supernatant was evaluated by ELISA. Each value
represents the mean7SD for three mice. *Po0.05, **Po0.01 compared with
OVA plus CpG-ODN. Similar results were obtained in three different
experiments.
2,000
1,500
1,000
500
0
Co
nt
ro
l
O
VA
Cp
G
+O
VA
IL
-1
2 
(pg
/m
l)
Cp
G
+O
VA
 
+
N
S3
98
a 2,000
1,500
1,000
500
0
IL
-1
0 
(pg
/m
l)
Co
nt
ro
l
O
VA
Cp
G
+O
VA
Cp
G
+O
VA
 
+
N
S3
98
b 30
25
20
15
10
5
0
PE
G
2 
(ng
/m
l)
Co
nt
ro
l
O
VA
Cp
G
+O
VA
Cp
G
+O
VA
 
+
N
S3
98
c
Figure 3. Effect of the COX-2 inhibitor on IL-12, IL-10, and PGE2 production in the skin. NS-398 (25 mg), OVA (50 mg), and CpG-ODN (50mg) were applied to
the skin, and the levels of cytokines in the skin were determined 12 hours later. IL-12, IL-10, and PGE2 concentrations were evaluated by ELISA. Each value
represents the mean7SD for three mice. *Po0.05 compared with OVA plus CpG-ODN. #Po0.05 compared with OVA.
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LN was determined by RT-PCR. As shown in Figure 4b, IL-10
mRNA expression induced by CpG-ODN treatment was
clearly reduced by NS-398. On the other hand, IL-12 mRNA
was clearly expressed in the LNs of NS-398-treated mice
(Figure 4b). These findings suggest that the migration of LCs
and dermal DCs which acquired the ability to produce IL-12
by NS-398 and CpG-ODN treatment, or direct delivery of
these drugs induce highly expression of IFN-g mRNA in the
draining LN. It is reported that IL-12 induces Th1 differentia-
tion (Hsieh et al., 1993; Trinchieri, 1993), and our experi-
ment shows that the IFN-g mRNA expression induced mainly
by Th1 in the LN was upregulated on the application of NS-
398 (Figure 4b).
COX-2 inhibitor enhances CTL induction by CpG-ODN
It is reported that treatment with CpG-ODN generates great
numbers of CTLs which have antitumor effects (Davis et al.,
1998; Miconnet et al., 2002). So we next examined whether
the COX-2 inhibitor NS-398 enhances the generation and
activity of CTLs induced by CpG-ODN. Splenocytes from
vaccinated mice were stimulated with mitomycin C-treated
E.G7-OVA cells and cultured for 5 days. CTLs were collected
and incubated with E.G7-OVA cells for 4 hours and the
amount of lactate dehydrogenase released was measured. As
shown in Figure 5, specific cell lysis was observed in
splenocytes prepared from CpG-ODN-treated mice and this
CTL activity was significantly increased in CpG-ODN plus
NS-398-treated mice. These results suggest that NS-398
enhances not only Th1-type immune responses but also CTLs
activities.
Effect of COX-2 inhibitor on tumor growth and survival
It is very important for tumor immune prophylaxis and tumor
therapy to induce antitumor responses by generating suffi-
cient numbers of tumor antigen-specific Th1 cells and CTLs.
We examined the effect of a COX-2 inhibitor on the
generation of antigen-specific Th1 cells and CTLs by CpG-
ODN and suggested that vaccination with such an inhibitor
from the skin increased the numbers and activity of these
cells. Subsequently, we examined the tumor immune
prophylaxis on transcutaneous vaccination with the COX-2
inhibitor. Following the transcutaneous vaccination, mice
were inoculated s.c. with E.G7-OVA tumor cells, and
subsequent tumor growth was assessed by measuring tumor
volume. Survival rate was calculated by counting surviving
mice. As shown in Figure 6a, tumor growth was inhibited in
CpG-ODN-treated mice and this inhibitory effect was
significantly enhanced when mice were treated with NS-
398. Furthermore, 60% of NS-398-treated mice survived 100
days, but only 10% of the mice treated with CpG-ODN only
survived (Figure 6b).
DISCUSSION
Vaccination is one of the most cost-effective ways to
prevent and control several diseases and there is still a great
need to develop a new generation of safer vaccines that can
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Figure 4. Effect of the COX-2 inhibitor on skin APC migration and mRNA expression in draining lymph nodes. (a) Twenty-four hours after the application of
NS-398 CpG-ODN, Alexa-488-conjugated OVA, or PBS (control) to the skin, the draining lymph nodes were removed. Lymph node single cells (106) were
incubated with phycoerythrin-conjugated anti-MHC class II mAb or phycoerythrin-conjugated anti-CD11c mAb and two-color fluorescence was analyzed with
FACScan. Following the application of NS-398, CpG-ODN, and OVA to the skin, the draining lymph nodes were removed 5 days after the last vaccination. The
cytokine mRNA expression in lymph nodes was determined by RT-PCR and normalized by b-actin levels (b). Each value represents the mean7SD for three
mice. *Po0.05 compared with OVA plus CpG-ODN. #Po0.05 compared with OVA. Similar results were obtained in three different experiments.
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be effectively administered by simple, economical,
and practical immunization procedures. Recently, there has
been a lot of interest in the potential of non-invasive routes,
such as via the skin, for tumor vaccine delivery (Seo et al.,
2000; Takigawa et al., 2001; Bins et al., 2005). Because
the skin-associated lymphoid tissue, comprised of powerful
APCs such as LCs and dermal DCs, re-circulating T cells,
and the regional LNs, ensures the efficient presentation
of tumor antigen to immunocompetent cells and induction of
strong immune responses. We have recently reported that
the administration of CpG-ODN through tape-stripped
skin induced an antigen-specific Th1-type immune
response and suggested that the skin is a potential site for
vaccination (Inoue et al., 2005a, b). In this study, we tried to
establish efficient Th1 and CTL priming strategies
against tumors, using CpG-ODN and a COX-2 inhibitor
applied to the skin.
Our examination showed that the skin is the best route of
administration for efficient Th1 and CTL activity following the
application of CpG-ODN and the COX-2 inhibitor, because
the production of IFN-g by splenocytes was remarkably
enhanced following application to the skin but not after i.p.
and i.v. injections (Figure 2). In our examination, the COX-2
inhibitor strongly suppressed T-cell function in a dose-
dependent manner, but enhanced the production of IL-12 by
APCs stimulated with CpG-ODN in vitro (data not shown). It is
suggested that the administration of a COX-2 inhibitor i.p. and
i.v. made it hard to deliver the drug to APCs. Thus, no
enhancement of IFN-g production was observed when the
COX-2 inhibitor was administrated i.p. and i.v. (Figure 2). On
the other hand, on transcutaneous application, the COX-2
inhibitor may be localized to the skin because of the
hydrophobicity of the drug. It is favorable that LCs and dermal
DCs exist in the skin and the drug may easily interact with
these cells. Indeed, APCs in the skin, especially LCs and
dermal DCs were known to produce IL-12 in response to CpG-
ODN, and this ability may be upregulated when NS-398 is
applied with CpG-ODN (Figure 3). Furthermore, the vaccina-
tion with NS-398 enhances the migration of antigen-bearing-
CD11c-positive cells to the draining LNs (Figure 4a). This
response may be explained by the direct activation of CD11c-
positive cells, especially LCs, by CpG-ODN with NS-398. And
this upregulation may be the one of the mechanisms of the
effective induction and generation of Th1 and CTLs by
transcuraneous vaccination with NS-398. Thus, transcuta-
neous vaccination may be useful to bring out the potential for
vaccination. However, the enhancement of the migration of
antigen-bearing-MHC class II-positive cells was not observed
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Figure 5. The COX-2 inhibitor enhances the effect of CpG-ODN on CTLs.
NS-398 (25 mg), OVA (50 mg), and CpG-ODN (50 mg) were applied to the skin,
and spleen cells were prepared 7 days after the last vaccination. To generate
CTLs, splenocytes were stimulated with mitomycin C-treated E.G7-OVA cells
and cultured for 5 days. Then, CTLs and E.G7-OVA cells were incubated for
4 hours at 371C. Supernatants were collected and the amount of lactate
dehydrogenase released was measured in triplicates. The specific lysis of
target cells was quantified using the formula (experimentaleffector
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spontaneous) 100. Each value represents the mean7SD for three mice.
*Po0.05 compared with OVA plus CpG-ODN. #Po0.05 compared with
OVA. Similar results were obtained in three different experiments.
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Figure 6. Effect of the COX-2 inhibitor on tumor growth and survival in mice vaccinated with CpG-ODN. (a, b) OVA (50 mg) (m), NS-398 (25 mg) plus OVA
(50mg) plus CpG-ODN (50mg) (J), and OVA (50 mg) plus CpG-ODN (50 mg) (K) were applied to the skin. One week after the last vaccination, mice were
inoculated s.c. with E.G7-OVA tumor cells (5 106 cells/mouse), and (a) subsequent tumor growth was assessed by taking an average of tumor diameters
measured with calipers and calculating tumor volume with the formula: tumor volume¼ (length) (width)2/2. (b) The rate of survival was determined by
counting surviving mice. Each value represents the mean7SD for ten mice. *Po0.05 compared with OVA plus CpG-ODN. Similar results were obtained in two
different experiments.
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even when vaccinated with NS-398. This response may come
from the difference in susceptibility of these cell populations to
NS-398.
Our findings suggested that transcutaneous vaccination
with a COX-2 inhibitor induces efficient Th1 priming. Th1-
dominant immunity plays a critical role in the induction of
antitumor immunity multiple helper functions such as the
capacity to enhance CTL priming of APCs and to promote
migration, proliferation, and cytotoxicity of tumor-specific
CTLs (Ridge et al., 1998; Marzo et al., 2000; Giuntoli et al.,
2002; Yu et al., 2003). Chamoto et al. (2004) reported that
adaptive transfer of Th1 induces effective antitumor immu-
nity. It is also reported that LCs and dermal DCs have an
effect on antigen cross-presentation and cross-priming to
generate CTLs (Ackerman and Cresswell, 2004; Heath et al.,
2004; Matsuo et al., 2004), and CpG-ODN enhances this
effect dependent on IFN-g, type-I IFN production, and MHC
class-I expression in these APCs (Cho et al., 2002; Kuchtey
et al., 2005). PGE2 exhibited dose-dependent inhibition of
these functions of APCs, therefore we expected an enhance-
ment of CTL induction on transcutaneous vaccination with a
COX-2 inhibitor which induces strong Th1 immune re-
sponses. Transcutaneous vaccination with CpG-ODN in-
duced antigen-specific tumor cell lysis and the COX-2
inhibitor remarkably enhanced this effect (Figure 5). These
results suggested that LCs and dermal DCs in COX-2
inhibitor-treated mice changed the production of PGE2 and
cytokines, and also MHC class-I expression. These APCs
migrated the LN and may assist CD8þ T cells to tumor
antigen-specific CTLs. Furthermore, it is very important for
tumor immune prophylaxis and tumor therapy to induce
antitumor responses by tumor antigen-specific Th1 cells and
CTLs. We demonstrated here that a COX-2 inhibitor
enhances the generation of antigen-specific Th1 cells and
CTLs by CpG-ODN, and transcutaneous vaccination with the
COX-2 inhibitor was effective in terms of tumor immune
prophylaxis, tumor growth inhibition, and survival (Figure 6).
We are now investigating the effect of this transcutaneous
vaccination for tumor therapy model, vaccinated after the
tumor inoculation, focus on the effect of co-application with
NS-398 in the generation and activation of Th1 cells, CTLs,
and NK cells in tumor-bearing mice.
CpG-ODNs are known to stimulate strong NK cell
responses, but in our experiments, NK cell-mediated
IFN-g production was not observed (Figure 1). It is because
that the activation of NK cell by CpG-ODNs were very
early responses. In fact, systemically injection of CpG-ODNs
induces the activation of NK and NK T cell in 4 hours after
the injection (Suzuki et al., 2004). On the other hands,
it is reported that activation of NK and NK T cell by
CpG-ODN was an indirect effect mediated by activated
APCs, and this response was shown in a week after
application of CpG-ODN. And then, the contribution of NK
and NK T cells in enhancement of antitumor immunity by
CpG-ODN is not yet elucidated, and additional studies
are needed.
Repeated CpG-ODN administration through the i.p.
route induces strongly reduced primary humoral immune
responses and immunoglobulin class switching with
multifocal liver necrosis and hemorrhagic ascites as a
side effect (Heikenwalder et al., 2004). All these side
effects were strictly dependent on the CpG-motif and
toll-like receptor-9, as neither the CpG-ODN treatment of
toll-like receptor-9 knockout mice nor the repetitive chal-
lenge of wild-type mice with non-stimulatory ODN was
immunotoxic or hepatotoxic. We succeeded in inducing
strong antitumor immunity with a transcutaneous vaccina-
tion. We expect the transcutaneous route to facilitate the
targeting of APCs and reduce the distribution of drugs in the
whole body compared to the i.p. or i.v. route. Therefore, we
consider that the skin is the most effective site for vaccination
with CpG-ODN despite these adverse effects, but additional
study is needed.
All these findings suggest that transcutaneous vaccination
with a COX-2 inhibitor is a very simple and effective way to
induce antitumor immunity and that such a vaccine is non-
invasive and effective. In addition, COX-2 inhibitors are
commonly used in clinical medicine, therefore this strategy
may be readily achievable when the use of CpG-ODN is
authorized.
MATERIALS AND METHODS
Animals and tumors
Specific pathogen-free C57BL/6 mice (male, 8–12 weeks old) were
purchased from SLC Co. Ltd. (Shizuoka, Japan). E.G7-OVA cells
(transfected with EL4 to express OVA) (Carbone and Bevan, 1990)
were obtained from the ATCC (Manassas, VA) and cultured in
complete medium consisting of Rosewell Park Memorial Institute-
1640 medium supplemented with 10% fetal calf serum, 100 U/ml
penicillin, 100mg/ml streptomycin, 2 mM L-glutamine, and 5
105 M 2-mercaptoethanol.
Reagents
The sequence for CpG-ODN was 50-TCCATGACGTTCCTGATG
CT-30, and HPLC-purified phosphorothioate ODN was obtained
from Sigma Genosys (Tokyo, Japan). The COX-2 inhibitor (NS-398)
was obtained from Sigma (Tokyo, Japan) and stocked in DMSO
(5 mg/ml).
Animal experiment and cytotoxicity assay
Animal use and relevant experimental procedures were approved by
the Tokyo University of Pharmacy and Life Science Committee on
the Care and Use of Laboratory Animals. Mice were anesthetized
with an i.p. injection of Nembutal (1.5 mg/mouse), the abdominal
skin was shaved, and then the stratum corneum was removed
by stripping with adhesive tape (Nichiban, Japan) six times.
NS-398 (25 mg/10ml; (dissolved in DMSO:PBS (phosphate-buffered
saline)¼ 1:1)) was applied onto the tape-stripped skin, and after
15 minutes CpG-ODN (50mg) and OVA (50 mg) in 50 ml of PBS
solution were applied. To boost the response, the same procedure
was applied to the tape-stripped skin 1 week later. Mice were
sacrificed at day 14. CTL activity was evaluated by the method
used to generate CTL. In brief, 5 106/ml of splenocytes depleted of
red blood cells were stimulated with mitomycin C (Sigma, Japan)-
treated E.G7-OVA cells (2.5 105/ml), and cultured in complete
medium for 5 days. Then, CTLs and E.G7-OVA cells (2 104)
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were incubated for 4 hours at 371C. Supernatants were collected
and the amount of lactate dehydrogenase released was measured
with a CytoTox 96 cytotoxicity assay kit (Promega, Japan). The
specific lysis of target cells was quantified using the formula
(experimentaleffector spontaneoustarget spontaneous)/(target
maximumtarget spontaneous) 100.
Preparation of mouse splenic cells
Following the application of NS-398, CpG-ODN, and OVA via
different routes, tape-stripped skin, i.p., or i.v., the spleen was
removed 7 days after the last vaccination, and splenic single cell
suspensions were prepared (Inoue et al., 2005a, b). To examine the
production of cytokines, spleen cells (5 105/well) were incubated
in Rosewell Park Memorial Institute-1640 medium supplemented
with 10% fetal calf serum, 100 U/ml penicillin, 100 mg/ml strepto-
mycin, 2 mM L-glutamine, and 5 105 M 2-mercaptoethanol for
24 hours in the presence of OVA (2 mg/ml).
Determination of cytokine levels
The level of IFN-g in the supernatant of splenic cells was routinely
determined with a sandwich ELISA using pairs of purified capture
and biotinylated detection mAbs (all obtained from Pharmingen, San
Diego, CA) recognizing murine IFN-g, according to the manufac-
turer’s directions.
Changes in OVA specific-antibody levels
Blood samples from mice treated with NS-398, CpG-ODN, and
OVA were collected 14 days after the last vaccination from the retro-
orbital plexus and sera were pooled. In brief, a 2-fold dilution of
mouse sera (50 ml) was poured into an OVA-coated ELISA plate, and
stood overnight to confirm that an immune reaction took place. The
plate was then washed four times with PBS containing 0.05%
Tween-20 (PBS-T), biotin-conjugated anti-mouse IgG2a mAb (ob-
tained from Pharmingen) was added, and the plate was stood at 41C
overnight. After a wash with PBS-T, avidin-conjugated peroxidase
was added and the absorbance at 450 nm was determined as
described previously (Inoue et al., 2005a, b).
Cytokine determination in the skin
Following the application of NS-398, CpG-ODN, and OVA to the
tape-stripped skin, the skin was removed 12 hours after the first
vaccination. The skin was excised and homogenated with the
Polytron homogenizer in 1 ml of saline containing protease
inhibitors (0.17 mg/ml phenylmethylsulphonyl fluoride, 0.02 mg/ml
leupeptin, and 0.01 mg/ml aprotinin). The homogenate was cen-
trifuged at 9,000 g for 10 minutes and the supernatant was collected.
The levels of IL-10, IL-12 p70, and PGE2 in the skin were routinely
determined with a sandwich ELISA using pairs of purified capture
and biotinylated detection mAbs (IL-10 and IL-12 p70 were obtained
from Pharmingen, and the PGE2 Enzyme Immunoassay Kit was
obtained from Oxford Biomedical Research, Oxford, MI) recogniz-
ing murine IL-10, IL-12 p70, and PGE2 according to the manufac-
turer’s directions.
Assay for transcutaneous vaccination induced APC migration
Following the application of NS-398, CpG-ODN, and Alexa-488-
conjugated OVA (obtained from Molecular Probes, Eugene, OR) to
the tape-stripped skin, the draining lymph nodes were removed
24 hours after the first vaccination. Lymph node single
cells (106) were incubated for 30 minutes on ice with phycoery-
thrin-conjugated anti-MHC class II mAb or phycoerythrin-conju-
gated anti-CD11c mAb (obtained from Pharmingen). Two-color
fluorescence was analyzed on FACScan (Becton Dickinson, Franklin
Lakes, NJ).
RT-PCR
Following the application of NS-398, CpG-ODN, and OVA to the
tape-stripped skin, the draining lymph nodes were removed 5 days
after the last vaccination. The cytokine mRNA expression in lymph
nodes was determined by RT-PCR and normalized by b-actin levels.
Total RNA (2 mg) was isolated with Isogen solution (Nippon Gene,
Toyama, Japan) as reported previously (Inoue et al., 2005a, b).
Complementary DNA was synthesized using SuperScript III. Then,
complementary DNAs were amplified with primers specific for each
cytokine (IL-12 p40, forward, 50-CAGAAGCTAACCATCTCCTGG
TTTG-30, reverse, 50-TCCGGAGTAATTTGGTGGTTCACAC-30; IL-
10, forward, 50-GGACAACATACTGCTAACCGACTC-30, reverse, 50-
AAAATCACTCTTCACCTGCTCCAC-30; IFN-g, forward, 50-CTCAA
GTGGCATAGATGT-30, reverse, 50-GAGATAATCTGGCTCTGCAG
GATT-30; b-actin, forward, 50-GCACCACACCTTCTACAATGAG-30,
reverse, 50-TTGGCATAGAGGTCTTTACGGA-30). The primers for
b-actin were used as an internal control. PCR cycles were as follows:
IL-12 p40 and IL-10 for 30 cycles, IFN-g and b-actin for 28 cycles.
Primers designed based on the mouse sequences were obtained from
Sigma Genosys (Tokyo, Japan).
Tumor growth and survival
For tumor development, mice were immunized twice as stated
above. One week after the last vaccination, mice were inoculated
s.c. with E.G7-OVA tumor cells (5 106 cells/mouse), and subse-
quent tumor growth was assessed by taking an average of tumor
diameters measured with calipers and calculating tumor volume
using the formula: tumor volume¼ (length) (width)2/2. The rate of
survival was determined by counting surviving mice. In both
experimental protocols, control mice were treated with an applica-
tion of saline to intact skin or tape-stripped skin.
Statistical analysis
The paired Student’s t-test was used to compare paired groups. An
analysis of variance was used for multi-group analysis. Values of
P40.05 were considered to indicate a lack of significance.
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